Jilin Province Tumor Hospital

Dual-target CAR-T cells in triple-negative breast cancer: recent advances and translational challenges

Treatment options for triple-negative breast cancer (TNBC) remain extremely limited, and patients have a poor prognosis. Although chimeric antigen receptor (CAR)-T cell therapy has achieved breakthroughs in haematological malignancies, its application in solid tumours such as TNB...

Tumor immune organoids support preclinical evaluation of cancer immunotherapies through comparative modelling and translational investigation

The response of cancer patients to immunotherapy varies significantly. However, there is still a lack of functional models that can accurately predict efficacy in vitro while preserving individual tumor immune characteristics of patients. This to some extent restricts the develop...

Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer

BackgroundPatients with extensive-stage small-cell lung cancer have poor outcomes, with a median overall survival of approximately 12 to 13 months. Tarlatamab (a bispecific T-cell engager targeting delta-like ligand 3 [DLL3] and CD3) was previously shown to improve survival as se...